NK-510

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameNK-510
Drug Alias NameNK-510
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBase Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesZhuhai Bestenco Technology Co LtdBase Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[8] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A